Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Nevena Damjanov, MD

Professor of Clinical Medicine
Attending Physician, Hospital of the University of Pennsylvania
Attending Physician, Penn Presbyterian Medical Center
Director of GI Oncology, Abramson Cancer Center at the Penn Presbyterian Medical Center
Director, Clinical Research Program, Abramson Cancer Center at the Penn Presbyterian Medical Center
Department: Medicine

Contact information
Penn Presbyterian Medical Center
51 North 39th Street
103A MAB
Philadelphia, PA 19104
Office: 215-662-8488
Fax: 215-243-3249
BA (Biology, Philosophy)
University of Pennsylvania, 1985.
MD (Internal Medicine)
Hahnemann University, 1989.
CTF (Leading Success)
Raymond and Ruth Perelman School of Medicine University of Pennsylvania, 2015.
Post-Graduate Training
Residency in Internal Medicine, M.S. Hershey Medical Center, 1989-1992.
Fellowship in Hematology/Oncology, University of Pennsylvania Medical Center, 1992-1996.
American Board of Internal Medicine (Internal Medicine), 1992.
American Board of Internal Medicine (Medical Oncology), 1995.
American Board of Internal Medicine (Hematology), 1996.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

V. Mazzaferro, B. El-Rayes, C. Cotsoglou, W. P. Harris, N. Damjanov, G. Masi, L. Rimassa, N. Personeni, F. Braiteh, V. Zagonel, K.P. Papadopoulos, T. Hall, Y. Wang, G. Abbadessa, B. Schwart, J. Kazakin, M. Droz Dit Busset, W. Shaib: ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J Clin Oncol 35, June 2017 Notes: Poster Discussion Presentation.

Mark H. O'Hara, Thomas Benjamin Karasic, Irina Vasilevskaya, Maryann Redlinger, Arturo Loaiza-Bonilla, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Kim Anna Reiss, Mark Alan Rosen, Daniel F Heitjan, Andrea B. Troxel, Ravi K. Amaravadi, Peter J. O'Dwyer: Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer J Clin Oncol 35, June 2017.

Lorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, Vittorina Zagonel, Marc Pracht, Elena Rota-Caremoli, Philippe Mathurin, William Harris, Luigi Bolondi, Maria Reig, Nevena Damjanov, Bruno Daniele, Camillo Porta, Vincenzo Mazzaferro, Giovanni Abbadessa, Brian Schwartz, Maria Lamar, Terri Goldberg, Armando Santoro, Jordi Bruix: Second-Line Tivantinib (ARQ 197) vs Placebo in Patients (Pts) with MET-High Hepatocellular Carcinoma (HCC): Results of the METIV-HCC Phase 3 Trial. J Clin Oncol 35, June 2017 Notes: Oral Presentation.

Braxton DR, Saxe D, Damjanov N, Stashek K, Shroff S, Morrissette JD, Tondon R, Furth EE.: Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma". Hum Pathol 62: 232-241, April 2017.

Rimassa, L., Reig, M., Abbadessa, G., Peck-Radosavljevic, M., Harris, W., Zagonel, V., Pastorelli, D., Rota Caremoli, E., Porta, C.,Damjanov, N., Patel, H., Daniele, B., Lamar, M., Schwartz, B., Goldberg, T., Santoro, A., Bruix, J.: Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma World J Gastroenterol 23(13): 2448-2452, April 2017.

Jacob E. Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter O’Dwyer, Mark O’Hara, Kim Reiss, Ursina Teitelbaum, Paul Wissel, Jeffery Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Berman, Jay Dorsey, Sydney M. Evans, Gary Kao, John. N. Lukens, John P. Plastaras, James M. Metz, Edgar Ben-Josef: A Phase I Dose Escalation Trial of Nab-Paclitaxel and Fixed Dose Radiation in Patients with Unresectable or Borderline Resectable Pancreatic Cancer Association for Clinical and Translational Science Annual Meeting April 2017.

Brown,J.C., Troxel, A.B., Ky, B., Damjanov, N., Zemel, B.S., Rickels, M.R., Rhim, A.D., Rustgi, A.K., Courneya, K.S., Schmitz, K.H.: A randomized phase II dose–response exercise trial among Colon Cancer Survivors: Purpose, Study Design, methods, and recruitment results, Contemporary Clinical Trials 47: 366–375, March 2016.

Lea Lowenfeld MD, Jashodeep Datta MD, Russell S. Lewis Jr., Matthew T. McMillan, Ronac Mamtani MD, Nevena Damjanov MD, Vinay Chandrasakhara MD, Giorgos Karakousis MD, Jeffrey Drebin MD PhD, Douglas Fraker MD, Robert E. Roses MD: Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Annals of Surgical Oncology 22(Suppl 3): S863-72, December 2015.

Vassallo,R; Prechtel-Dunphy,E; Damjanov,N; Tsikouras,A; Favatella,J; Kasbekar,N.: Impact of Comprehensive Pharmacy Services on Patient Centered Outcomes in an Oncology Clinic. UHC Pharmacy Council Meeting: New Orleans, LA December 2015 Notes: "Poster Presentation"

E.M. Egert, R.D. Johnson, M.M. Watts, J. Booty, N. Damjanov, R. Mohr, M. Lee, N.S. Mungiole, D.E. Kaplan, J. Griffiths, H.A. Shaikh, R.C. Hawley, M.S. Ghosh: A Regional Multidisciplinary Liver Tumor Board improves Access to Hepatocellular Carcinoma Treatment for Patients Geographically Distant from Tertiary Medical Center. AASLD, The Liver Meeting 2015(521), November 2015 Notes: "Poster Presentation"

back to top
Last updated: 05/07/2017
The Trustees of the University of Pennsylvania
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration